| Dr Robert S Dealy, MD | |
|
7 Prospect St., Nashua, NH 03060 | |
| (603) 889-6147 | |
| (603) 883-1568 |
| Full Name | Dr Robert S Dealy |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 7 Prospect St., Nashua, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215900469 | NPI | - | NPPES |
| 000808209 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 048533 (Connecticut) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | LT3510 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert S Dealy, MD 7 Prospect St., Nashua, NH 03060 Ph: (603) 889-6147 | Dr Robert S Dealy, MD 7 Prospect St., Nashua, NH 03060 Ph: (603) 889-6147 |
News Archive
New research published in The Lancet shows that the use of vital life-saving generic (and supposedly inexpensive) medicines for prevention in people with existing heart disease is poor worldwide. In low-income and middle-income countries these medicines are not widely available and, when available, can often be unaffordable. In rich countries, although such medicines are both available and affordable, 35% to 50% of patients who have heart disease or a previous stroke still do not receive them.
A research team led by Michael Fox, a professor at the Fralin Biomedical Research Institute at VTC, has identified the type of brain cell that produces collagen 19, a protein that is crucial for the formation of inhibitory circuits in the brain.
Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').
ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.
› Verified 1 days ago
Santharam Yadati, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 436 Amherst St Ste 101, Nashua, NH 03063 Phone: 603-627-4764 Fax: 603-577-9595 | |
Pamela N Olsson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Dr. Kimberly K Whitesell, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Dr. Cynthia Brown Stevens, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7h Black Oak Dr, Nashua, NH 03062 Phone: 703-509-2753 | |
Bettina Peyton, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 22 Prospect Street, Home Health & Hospice, Nashua, NH 03060 Phone: 603-882-2941 | |
Andreja Packard, MD PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-577-5300 Fax: 603-577-5305 |